memantine has been researched along with Aggression in 13 studies
Aggression: Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 9.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 9.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice." | 7.70 | Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000) |
| "Patients with moderate-to-severe AD with Neuropsychiatric Inventory (NPI) total score ≥13 and NPI agitation/aggression score ≥1 were randomized to placebo or 20-mg memantine in a double-blind, 24-week trial." | 5.17 | A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. ( Boneva, N; Gauthier, S; Herrmann, N; Lemming, OM, 2013) |
| "The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 5.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
| " The current retrospective analysis evaluated the efficacy and safety of memantine in a subpopulation of patients with Alzheimer's disease exhibiting behavioral symptoms of agitation/aggression or psychosis at baseline." | 5.13 | Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. ( Ballard, CG; Cooper, JA; Loft, H; Wilcock, GK, 2008) |
| "The current experiments explore aggression and medial prefrontal cortex (mPFC) glutamate as consequences of withdrawal from intermittent access to EtOH and changes in aggression and mPFC glutamate caused by NMDAR antagonists memantine and ketamine." | 3.81 | Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice. ( DeBold, JF; Holly, EN; Hwa, LS; Miczek, KA; Nathanson, AJ; Newman, EL; Shimamoto, A; Tayeh, JK; Wilens, AR, 2015) |
| "The present study aimed to evaluate the effects of low-affinity NMDA receptor channel blockers (memantine and MRZ 2/579) on aggression facilitated by morphine withdrawal in mice." | 3.70 | Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. ( Bespalov, AY; Sukhotina, IA, 2000) |
| "Memantine was initiated, and the dose was titrated to 10 mg twice daily." | 1.33 | Antipsychotic dose-sparing effect with addition of memantine. ( Sleeper, RB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Nordman, JC | 1 |
| Bartsch, CJ | 1 |
| Li, Z | 1 |
| Herrmann, N | 2 |
| Gauthier, S | 1 |
| Boneva, N | 1 |
| Lemming, OM | 1 |
| Gabryelewicz, T | 1 |
| Hwa, LS | 1 |
| Nathanson, AJ | 1 |
| Shimamoto, A | 1 |
| Tayeh, JK | 1 |
| Wilens, AR | 1 |
| Holly, EN | 1 |
| Newman, EL | 1 |
| DeBold, JF | 1 |
| Miczek, KA | 1 |
| Ballard, C | 1 |
| Corbett, A | 1 |
| Chitramohan, R | 1 |
| Aarsland, D | 1 |
| Osborn, GG | 1 |
| Saunders, AV | 1 |
| Cappell, J | 1 |
| Eryavec, GM | 1 |
| Lanctôt, KL | 1 |
| Rodríguez-Arias, M | 1 |
| Maldonado, C | 1 |
| Aguilar, MA | 1 |
| Miñarro, J | 1 |
| Minkeviciene, R | 1 |
| Banerjee, P | 1 |
| Tanila, H | 1 |
| Sleeper, RB | 1 |
| Wilcock, GK | 1 |
| Ballard, CG | 1 |
| Cooper, JA | 1 |
| Loft, H | 1 |
| Ossowska, G | 1 |
| Klenk-Majewska, B | 1 |
| Szymczyk, G | 1 |
| Sukhotina, IA | 1 |
| Bespalov, AY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type[NCT00857649] | Phase 3 | 369 participants (Actual) | Interventional | 2003-12-31 | Terminated | ||
| Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia[NCT00401167] | Phase 4 | 32 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from Baseline in Neuropsychiatric Inventory (NPI) total score.~NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -3.90 |
| Placebo | -5.13 |
"Change from Baseline in Severe Impairment Battery (SIB) total score.~SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -2.34 |
| Placebo | -1.86 |
"Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score.~ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -4.36 |
| Placebo | -2.56 |
"Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score.~CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from 1 = Never to 7 = Several times an hour. Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | -0.26 |
| Placebo | -1.16 |
"Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline.~CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from 1 = marked improvement to 7 = marked worsening. A score of 4 indicates no change." (NCT00857649)
Timeframe: Baseline to Week 24
| Intervention | Scores on a scale (Mean) |
|---|---|
| Memantine | 4.68 |
| Placebo | 4.63 |
3 reviews available for memantine and Aggression
| Article | Year |
|---|---|
[Pharmacological treatment of behavioral symptoms in dementia patients].
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; | 2014 |
Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
Topics: Aged; Aggression; Alzheimer Disease; Anticonvulsants; Antidepressive Agents, Second-Generation; Anti | 2009 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory A | 2010 |
3 trials available for memantine and Aggression
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antiparkinson Agents; Double-Blind Method; F | 2013 |
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Topics: Aggression; Alzheimer Disease; Caregivers; Dopamine Agents; Female; Humans; Long-Term Care; Male; Me | 2011 |
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Topics: Aged; Aggression; Alzheimer Disease; Delusions; Dopamine Agents; Female; Hallucinations; Humans; Mal | 2008 |
7 other studies available for memantine and Aggression
| Article | Year |
|---|---|
Opposing effects of NMDA receptor antagonists on early life stress-induced aggression in mice.
Topics: Adverse Childhood Experiences; Aggression; Animals; Dizocilpine Maleate; Humans; Ketamine; Memantine | 2022 |
Aggression and increased glutamate in the mPFC during withdrawal from intermittent alcohol in outbred mice.
Topics: Aggression; Animals; Behavior, Animal; Ethanol; Excitatory Amino Acid Antagonists; Glutamic Acid; Ke | 2015 |
Memantine does not block antiaggressive effects of morphine in mice.
Topics: Adaptation, Psychological; Aggression; Animals; Excitatory Amino Acid Antagonists; Male; Memantine; | 2002 |
Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Animals; Dopamine Agents; Humans; Male; Maze Learning; Memantine; Mic | 2004 |
Antipsychotic dose-sparing effect with addition of memantine.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combinatio | 2005 |
The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats.
Topics: Aggression; Animals; Chronic Disease; Dizocilpine Maleate; Electroshock; Excitatory Amino Acid Antag | 1997 |
Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice.
Topics: Aggression; Animals; Cyclopentanes; Excitatory Amino Acid Antagonists; Male; Memantine; Mice; Morphi | 2000 |